Last reviewed · How we verify
GV-971 capsule
At a glance
| Generic name | GV-971 capsule |
|---|---|
| Also known as | GV-971 |
| Sponsor | First Affiliated Hospital Xi'an Jiaotong University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules (GV-971) (PHASE4)
- Long-term Efficacy and Safety Study of GV-971 (PHASE4)
- Efficacy and Safety of Memantine and Sodium Oligomannate in Patients With Moderate to Severe Alzheimer's Disease (PHASE4)
- A Study to Assess the Safety and Pharmacokinetics of Oral Sodium Oligo-mannurarate (GV-971) in Healthy Chinese Subjects (PHASE1)
- An Efficacy and Safety Study of Sodium Oligo-mannurarate (GV-971) Capsule for the Treatment of Alzheimer's Disease (PHASE3)
- A Study to Assess the Bioavailability of Oral Sodium Oligo-mannurarate (GV-971) in Healthy Chinese Male Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GV-971 capsule CI brief — competitive landscape report
- GV-971 capsule updates RSS · CI watch RSS
- First Affiliated Hospital Xi'an Jiaotong University portfolio CI